Non-Coding RNA as a Biomarker in Lung Cancer
Non-Coding RNA · 30.09.2024 · 10 (5) · 50
DOI: 10.3390/ncrna10050050 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Non-Coding RNA, online erschienen am 30.09.2024. Verfasst von Chahat Suri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Lung cancer remains one of the most prevalent and deadly cancers globally, with high mortality rates largely due to late-stage diagnosis, aggressive progression, and frequent recurrence. Despite advancements in diagnostic techniques and therapeutic interventions, the overall prognosis for lung cancer patients continues to be dismal.
Method
Emerging research has identified non-coding RNAs (ncRNAs), including microRNAs, long non-coding RNAs, and circular RNAs, as critical regulators of gene expression, significantly influencing cancer biology. These ncRNAs play pivotal roles in various aspects of lung cancer pathogenesis, including tumor initiation, progression, metastasis, and resistance to therapy.
Results
We provide a comprehensive analysis of the current understanding of ncRNAs in lung cancer, emphasizing their potential as biomarkers for early diagnosis, prognostication, and the prediction of the therapeutic response. We explore the biological functions of ncRNAs, their involvement in key oncogenic pathways, and the molecular mechanisms by which they modulate gene expression and cellular processes in lung cancer. Furthermore, this review highlights recent advances in ncRNA-based diagnostic tools and therapeutic strategies, such as miRNA mimics and inhibitors, lncRNA-targeted therapies, and circRNA-modulating approaches, offering promising avenues for personalized medicine.
Conclusion
Finally, we discuss the challenges and future directions in ncRNA research, including the need for large-scale validation studies and the development of efficient delivery systems for ncRNA-based therapies. This review underscores the potential of ncRNAs to revolutionize lung cancer management by providing novel diagnostic and therapeutic options that could improve patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
- Department of Biochemistry, C.C.M. Medical College, Bhilai 490020, Chhattisgarh, India.
- Department of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur 495009, Chhattisgarh, India.
- Department of Immunopathology, Institute of lungs Health and Immunity, Comprehensive Pnemology Center, Helmholtz Zentrum, Neuherberg, 85764 Munich, Germany.
- Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Neuherberg, 85764 Munich, Germany.
ORCID-Profile: Chahat Suri, Lvks Bhaskar, Henu Kumar Verma
Zitieren
APA
Suri, C., Swarnkar, S., Bhaskar, L., & Verma, H. K. (2024). Non-Coding RNA as a Biomarker in Lung Cancer. Non-Coding RNA, 10(5), 50. https://doi.org/10.3390/ncrna10050050
Vancouver
Suri C, Swarnkar S, Bhaskar L, Verma HK. Non-Coding RNA as a Biomarker in Lung Cancer. Non-Coding RNA. 2024;10(5):50. doi:10.3390/ncrna10050050
BibTeX
@article{Suri2024,
author = {Suri, Chahat and Swarnkar, Shashikant and Bhaskar, Lvks and Verma, Henu Kumar},
title = {Non-Coding RNA as a Biomarker in Lung Cancer},
journal = {Non-Coding RNA},
year = {2024},
volume = {10},
number = {5},
pages = {50},
doi = {10.3390/ncrna10050050}
}
EUVIMED